ATE330606T1 - Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden - Google Patents

Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden

Info

Publication number
ATE330606T1
ATE330606T1 AT93923724T AT93923724T ATE330606T1 AT E330606 T1 ATE330606 T1 AT E330606T1 AT 93923724 T AT93923724 T AT 93923724T AT 93923724 T AT93923724 T AT 93923724T AT E330606 T1 ATE330606 T1 AT E330606T1
Authority
AT
Austria
Prior art keywords
nmda receptor
neuronal damage
mediated neuronal
mammal
preventing nmda
Prior art date
Application number
AT93923724T
Other languages
English (en)
Inventor
Stuart A Lipton
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/949,342 external-priority patent/US5234956A/en
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE330606T1 publication Critical patent/ATE330606T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT93923724T 1992-09-22 1993-09-22 Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden ATE330606T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/949,342 US5234956A (en) 1991-04-19 1992-09-22 Method of preventing NMDA receptor complex-mediated neuronal damage
US08/025,028 US5455279A (en) 1991-04-19 1993-03-02 Regimen method of mediating neuronal damage using nitroglycerine

Publications (1)

Publication Number Publication Date
ATE330606T1 true ATE330606T1 (de) 2006-07-15

Family

ID=26699179

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93923724T ATE330606T1 (de) 1992-09-22 1993-09-22 Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden

Country Status (8)

Country Link
US (3) US5455279A (de)
EP (1) EP0661973B1 (de)
AT (1) ATE330606T1 (de)
AU (1) AU5348194A (de)
DE (1) DE69334035T2 (de)
DK (1) DK0661973T3 (de)
ES (1) ES2264122T3 (de)
WO (1) WO1994006428A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002810A1 (en) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
ES2182843T3 (es) 1993-04-20 2003-03-16 Merck & Co Inc Subunidades de receptor humano de n-metil-d-aspartato, acidos nucleicos que codifican las mismas y su uso.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US5807847A (en) * 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
AU4030097A (en) * 1996-09-03 1998-03-26 Yeda Research And Development Co. Ltd. Central nervous system-derived immune privilege factor and uses thereof
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
EP0979073A4 (de) * 1997-03-31 2004-04-07 Childrens Medical Center Nitrosylierung zur inaktivierung apoptotischer enzyme
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6277891B1 (en) 1997-07-11 2001-08-21 The Johns Hopkins University Nitric oxide inhibits rhinovirus infection
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
JPH11217330A (ja) * 1998-01-30 1999-08-10 Sumitomo Pharmaceut Co Ltd 神経栄養因子分泌促進剤
EP1013272A1 (de) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Beeinflussung der Aktivität eines Stickoxidradikalherstellungsweges zur Behandlung von mit freien Sauerstoffradikalen verbundenen Krankheiten
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
US6255280B1 (en) 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
GB9908175D0 (en) * 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
US6432434B1 (en) * 1999-04-22 2002-08-13 The United States Of America As Represented By The Secretary Of The Army Treatment of and/or prophylaxis against brain and spinal cord injury
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
WO2000074672A1 (en) * 1999-06-09 2000-12-14 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CA2414941C (en) 2000-08-11 2010-12-14 David R. Whitlock Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
JP2004515477A (ja) * 2000-12-07 2004-05-27 ニューロモレキュラー インコーポレイテッド Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法
EP1852113A3 (de) * 2000-12-07 2008-03-12 Neuromolecular Inc. Verfahren zur Behandlung neuropsychiatrischer Erkrankungen mit NMDA-Rezeptorantagonisten
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
CN1308438C (zh) * 2002-01-11 2007-04-04 大卫·R·怀特洛克 含有氨氧化细菌的化合物以及使用的方法
AU2003269810A1 (en) * 2002-04-04 2004-02-16 Children's Medical Center Corporation Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
US20050148673A1 (en) * 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
EP1667646A4 (de) * 2003-09-26 2007-07-04 David R Whitlock Verfahren zur verwendung von ammoniak-oxidierenden bakterien
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
CN101389315A (zh) 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
KR101406456B1 (ko) 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
WO2007116458A1 (ja) * 2006-03-30 2007-10-18 Tohru Hasegawa 神経変性疾患治療薬
US20100190815A1 (en) * 2006-09-08 2010-07-29 Kyowa Hakko Bio Co., Ltd. Hypertension-ameliorating agent
EP2111858A1 (de) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Neue Behandlung für Morbus Alzheimer
IT1398507B1 (it) * 2009-01-13 2013-03-01 Giellepi Chemicals S P A Composizione per il trattamento di neuropatie
US9023890B2 (en) * 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
SG182522A1 (en) 2010-01-27 2012-08-30 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
US9452117B2 (en) 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
EP2948135B1 (de) 2013-01-25 2019-01-02 Case Western Reserve University Zusammensetzungen und verfahren zur behandlung von erkrankungen mit pervasiver entwicklung
AU2015247710B2 (en) 2014-04-15 2021-09-09 Aobiome Llc Ammonia-oxidizing Nitrosomonas eutropha strain D23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
US4064139A (en) * 1975-04-07 1977-12-20 Merck & Co., Inc. Substituted 9,10-dihydroanthracen-9,10-imines
US4399141A (en) * 1977-09-19 1983-08-16 Merck & Co., Inc. 5-Alkyl or hydroxyalkyl substituted-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines and anticonvulsant use thereof
US4374838A (en) * 1977-09-19 1983-02-22 Merck & Co., Inc. Dibenzo[a,d]cycloocten-5,12-(and 6,12)-imines
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4513137A (en) * 1981-04-09 1985-04-23 The University Of Akron Iodonium salts
US4351847A (en) * 1981-06-26 1982-09-28 Pennwalt Corporation Antiviral alpha, alpha-dialkyl adamantylethylamines
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists
US4736048A (en) * 1986-06-04 1988-04-05 Dow Corning Corporation Pressure sensitive adhesive release liner and fluorosilicone compounds, compositions and method therefor
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
EP0341264A4 (en) * 1987-01-23 1991-03-20 The General Hospital Corporation Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
WO1991002810A1 (en) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5264371A (en) * 1989-11-22 1993-11-23 Neurex Corporation Screening method for neuroprotective compounds
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
EP0581856B1 (de) * 1991-04-19 1999-07-14 The Children's Medical Center Corporation Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden

Also Published As

Publication number Publication date
EP0661973A4 (de) 1999-12-22
US5747545A (en) 1998-05-05
US5455279A (en) 1995-10-03
EP0661973B1 (de) 2006-06-21
DK0661973T3 (da) 2006-10-30
ES2264122T3 (es) 2006-12-16
DE69334035D1 (de) 2006-08-03
EP0661973A1 (de) 1995-07-12
WO1994006428A1 (en) 1994-03-31
AU5348194A (en) 1994-04-12
US5801203A (en) 1998-09-01
DE69334035T2 (de) 2006-12-28

Similar Documents

Publication Publication Date Title
ATE330606T1 (de) Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden
EP0313305A3 (de) Chelatbildner enthaltende Lichtschutzmittel
IS4185A (is) Hliðstæð aðferð til framleiðslu fenýlsúlfonylamino-pýrimidines afleiða
DE60005688D1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
DE69229598D1 (de) Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden
DK0480077T3 (da) Fremgangsmåde til fremstilling af carnosinsyre
GR3021364T3 (en) Composition and method of enhancing sun tanning.
DE69129861T2 (de) Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
GB9406857D0 (en) Improvements in or relating to organic compounds
ATE185066T1 (de) Lösung zur verwendung gegen den pilzbefall von nägeln
ATE139445T1 (de) Verwendung von zinkionen zur behandlung der periodontitis
DE69010162T2 (de) Zusammensetzung zur Behandlung von Entzündung.
DE69407272D1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
DE59308292D1 (de) Substituierte triole
DE69625354T2 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
DE59200469D1 (de) Verfahren zum mehrstufigen bearbeiten von zähnen an sägeblättern sowie sägenbearbeitungsmaschine zum durchführen des verfahrens.
BR0205473A (pt) Composição cosmética ou dermatológica de uso tópico, uso de uma composição, processo para melhorar a estabilidade de pelo menos um derivado do dibenzoilmetano e uso de um derivado de 2-hidroxibenzofenona amino-substituìdo
ATE162794T1 (de) Schrittweise entfernung von monosacchariden vom reduzierenden ende von oligosacchariden und verwendungen davon
DE68911132T2 (de) Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils.
DE69228814D1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69203441D1 (de) Verfahren zum wälzschleifen von kronrädern.
AU7358691A (en) Tenidap as an inhibitor of the release of elastage by neutrophils
DE69131058T2 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
BG101325A (en) Use of muramyl peptide compounds
GR1001287B (el) Μεθοδος παρασκευης φαρμακου για τη θεραπεια των ουλιτιδων.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0661973

Country of ref document: EP